III

INIFY LABORATORIES AB

No trades
See on Supercharts
Market capitalization
‪452.37 M‬NOK
−1.20NOK
‪−53.10 M‬NOK
‪1.19 M‬NOK
‪6.11 M‬
Beta (1Y)
−0.72

About INIFY LABORATORIES AB

CEO
Fredrik Palm
Website
Headquarters
Solna
Employees (FY)
22
Founded
2021
ISIN
SE0017486103
FIGI
BBG0189Y39P7
INIFY Laboratories AB engages in the provision of cancer diagnostics through laboratory services within pathology. It offers services to urologists and hospitals with short and repeatable response time in terms of a structured diagnosis report sent directly into electronic health record system. The company was founded on November 10, 2021 and is headquartered in Solna, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of INIFY is 10.00 NOK — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OSL exchange INIFY LABORATORIES AB stocks are traded under the ticker INIFY.
INIFY stock is 5.00% volatile and has beta coefficient of −0.72. Check out the list of the most volatile stocks — is INIFY LABORATORIES AB there?
Yes, you can track INIFY LABORATORIES AB financials in yearly and quarterly reports right on TradingView.
INIFY stock hasn't changed in a week, the month change is a 2.88% rise, over the last year INIFY LABORATORIES AB has showed a 26.58% increase.
INIFY net income for the last quarter is ‪−14.68 M‬ NOK, while the quarter before that showed ‪−10.44 M‬ NOK of net income which accounts for −40.62% change. Track more INIFY LABORATORIES AB financial stats to get the full picture.
No, INIFY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, INIFY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INIFY LABORATORIES AB stock right from TradingView charts — choose your broker and connect to your account.
INIFY reached its all-time high on Jul 7, 2023 with the price of 17.00 NOK, and its all-time low was 4.00 NOK and was reached on Jun 20, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 22.00 employees. See our rating of the largest employees — is INIFY LABORATORIES AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INIFY LABORATORIES AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INIFY LABORATORIES AB stock shows the sell signal. See more of INIFY LABORATORIES AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INIFY LABORATORIES AB EBITDA is ‪−51.28 M‬ NOK, and current EBITDA margin is ‪−4.31 K‬%. See more stats in INIFY LABORATORIES AB financial statements.